These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 20127560)

  • 1. Emerging trends in ion channel-based assays for predicting the cardiac safety of drugs.
    Witchel HJ
    IDrugs; 2010 Feb; 13(2):90-6. PubMed ID: 20127560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. QT interval prolongation and cardiac risk assessment for novel drugs.
    Picard S; Lacroix P
    Curr Opin Investig Drugs; 2003 Mar; 4(3):303-8. PubMed ID: 12735231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early evaluation of compound QT prolongation effects: a predictive 384-well fluorescence polarization binding assay for measuring hERG blockade.
    Deacon M; Singleton D; Szalkai N; Pasieczny R; Peacock C; Price D; Boyd J; Boyd H; Steidl-Nichols JV; Williams C
    J Pharmacol Toxicol Methods; 2007; 55(3):238-47. PubMed ID: 17141530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A place for high-throughput electrophysiology in cardiac safety: screening hERG cell lines and novel compounds with the ion works HTTM system.
    Guthrie H; Livingston FS; Gubler U; Garippa R
    J Biomol Screen; 2005 Dec; 10(8):832-40. PubMed ID: 16234341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Automated electrophysiology in the preclinical evaluation of drugs for potential QT prolongation.
    Guo L; Guthrie H
    J Pharmacol Toxicol Methods; 2005; 52(1):123-35. PubMed ID: 15936217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro profiling against ion channels beyond hERG as an early indicator of cardiac risk.
    Chen MX; Helliwell RM; Clare JJ
    Curr Opin Mol Ther; 2009 Jun; 11(3):269-81. PubMed ID: 19479660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of a small molecule activator of the human ether-a-go-go-related gene (HERG) cardiac K+ channel.
    Kang J; Chen XL; Wang H; Ji J; Cheng H; Incardona J; Reynolds W; Viviani F; Tabart M; Rampe D
    Mol Pharmacol; 2005 Mar; 67(3):827-36. PubMed ID: 15548764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ILSI-HESI cardiovascular safety subcommittee initiative: evaluation of three non-clinical models of QT prolongation.
    Hanson LA; Bass AS; Gintant G; Mittelstadt S; Rampe D; Thomas K
    J Pharmacol Toxicol Methods; 2006; 54(2):116-29. PubMed ID: 16843688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative pharmacology of guinea pig cardiac myocyte and cloned hERG (I(Kr)) channel.
    Davie C; Pierre-Valentin J; Pollard C; Standen N; Mitcheson J; Alexander P; Thong B
    J Cardiovasc Electrophysiol; 2004 Nov; 15(11):1302-9. PubMed ID: 15574182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acquired QT interval prolongation and HERG: implications for drug discovery and development.
    Finlayson K; Witchel HJ; McCulloch J; Sharkey J
    Eur J Pharmacol; 2004 Oct; 500(1-3):129-42. PubMed ID: 15464027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blockade of the I(Ks) potassium channel: an overlooked cardiovascular liability in drug safety screening?
    Towart R; Linders JT; Hermans AN; Rohrbacher J; van der Linde HJ; Ercken M; Cik M; Roevens P; Teisman A; Gallacher DJ
    J Pharmacol Toxicol Methods; 2009; 60(1):1-10. PubMed ID: 19439185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of functional and binding assays in cells expressing either recombinant or endogenous hERG channel.
    Murphy SM; Palmer M; Poole MF; Padegimas L; Hunady K; Danzig J; Gill S; Gill R; Ting A; Sherf B; Brunden K; Stricker-Krongrad A
    J Pharmacol Toxicol Methods; 2006; 54(1):42-55. PubMed ID: 16326118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Whole-cell configuration of the patch-clamp technique in the hERG channel assay to predict the ability of a compound to prolong QT interval.
    Goineau S; Legrand C; Froget G
    Curr Protoc Pharmacol; 2012 Jun; Chapter 10():Unit 10.15.. PubMed ID: 22684720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of the HERG channel by droperidol depends on channel gating and involves the S6 residue F656.
    Luo T; Luo A; Liu M; Liu X
    Anesth Analg; 2008 Apr; 106(4):1161-70, table of contents. PubMed ID: 18349188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patch-clamp technique in ESC-derived cardiomyocytes.
    Liu J; Backx PH
    Methods Mol Biol; 2014; 1181():203-14. PubMed ID: 25070339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. hERG-related drug toxicity and models for predicting hERG liability and QT prolongation.
    Raschi E; Ceccarini L; De Ponti F; Recanatini M
    Expert Opin Drug Metab Toxicol; 2009 Sep; 5(9):1005-21. PubMed ID: 19572824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular interaction of droperidol with human ether-a-go-go-related gene channels: prolongation of action potential duration without inducing early afterdepolarization.
    Schwoerer AP; Blütner C; Brandt S; Binder S; Siebrands CC; Ehmke H; Friederich P
    Anesthesiology; 2007 May; 106(5):967-76. PubMed ID: 17457128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. hERG (KCNH2 or Kv11.1) K+ channels: screening for cardiac arrhythmia risk.
    Bowlby MR; Peri R; Zhang H; Dunlop J
    Curr Drug Metab; 2008 Nov; 9(9):965-70. PubMed ID: 18991593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of HERG potassium channel current by the class 1a antiarrhythmic agent disopyramide.
    Paul AA; Witchel HJ; Hancox JC
    Biochem Biophys Res Commun; 2001 Feb; 280(5):1243-50. PubMed ID: 11162661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The antipsychotic agent sertindole is a high affinity antagonist of the human cardiac potassium channel HERG.
    Rampe D; Murawsky MK; Grau J; Lewis EW
    J Pharmacol Exp Ther; 1998 Aug; 286(2):788-93. PubMed ID: 9694935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.